GSA Capital Partners’s Revolution Medicines RVMD Stock Holding History

GSA Capital Partners’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.15M	Buy	+11,864	New	+$1.2M	0.07%	405
2025 Q4	–	Sell	-10,080	Closed	-$471K	–	2038
2025 Q3	$471K	Buy	10,080 +1,594	+19%	+$62.4K	0.04%	884
2025 Q2	$312K	Buy	+8,486	New	+$326K	0.02%	1227
2024 Q3	–	Sell	-31,467	Closed	-$1.22M	–	1959
2024 Q2	$1.22M	Buy	31,467 +23,666	+303%	+$885K	0.09%	377
2024 Q1	$251K	Buy	+7,801	New	+$231K	0.02%	1302
2023 Q3	–	Sell	-18,762	Closed	-$502K	–	1847
2023 Q2	$502K	Sell	18,762 -20,595	-52%	-$505K	0.05%	731
2023 Q1	$852K	Buy	+39,357	New	+$969K	0.08%	402
2022 Q3	–	Sell	-42,184	Closed	-$822K	–	1818
2022 Q2	$822K	Buy	+42,184	New	+$821K	0.12%	215

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GSA Capital Partners's RVMD Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Revolution Medicines (RVMD) in Q1 2026: 11,864 shares worth $1.15M. The stake represents 0.07% of the portfolio and ranks #405 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in RVMD as recently as Q3 2025.

GSA Capital Partners first reported a position in RVMD in Q2 2022 and has held it in 8 quarters since. The position peaked at $1.22M in Q2 2024. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

GSA Capital Partners held 11,864 shares of Revolution Medicines worth $1.15M as of Q1 2026.
Revolution Medicines was a new GSA Capital Partners position in Q1 2026.
Revolution Medicines made up 0.07% of GSA Capital Partners's portfolio in Q1 2026, its #405 holding.
GSA Capital Partners first reported a position in Revolution Medicines in Q2 2022 and has held it in 8 quarters since.
GSA Capital Partners's Revolution Medicines position peaked at $1.22M in Q2 2024.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.